SMARCA4 and small cell carcinoma: Consistent with this hypothesis, our data demonstrated that SMARCA4/A2-deficient small cell cancer of the ovary hypercalcemia type (SCCOHT) and non-small cell lung cancer (NSCLC) models are acutely sensitive to BETi at low nanomolar concentrations in vitro as well as in vivo (20 mg/kg per day).88 Further support for this premise comes from the observation that ectopic expression of SMARCA4 was found to confer partial resistance to BETi.